Personalized blood pressure targets for cardiogenic shock
Part of Heart & circulation clinical trials.
This trial tests whether setting a personalized blood pressure goal for each person in cardiogenic shock improves recovery compared to standard care. It may help if you have severe shock and can be enrolled within the first 24 hours.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have cardiogenic shock (severe heart failure causing low blood pressure and organ damage) that is classified as moderate to severe.
- You have not been on heart-supporting medications (catecholamines) for more than 24 hours straight.
- You do not have severe chronic kidney disease (stage 4 or 5) or need dialysis.
- You are not already on a mechanical heart pump before entering the study.
- You do not have a known allergy to the drug norepinephrine (used to raise blood pressure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two blood pressure targets in people with cardiogenic shock after a heart attack. It looks at whether the lower target can improve outcomes and help evaluate treatment costs.
This study looks at how people with cardiogenic shock (or very low blood pressure from heart causes) do after treatment in a specialized cardiovascular ICU. It also examines whether care by heart critical-care specialists affects outcomes.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
This study looks at whether adding two simple blood test markers to a standard heart failure score can better predict recovery in people with cardiogenic shock, a condition where the heart cannot pump enough blood. The goal is to help doctors tailor treatment for each patient.
This trial studies whether using a special pressure-monitoring tube in the heart’s main artery (a pulmonary artery catheter) helps people who are in cardiogenic shock from weak heart pumping. If you qualify, the goal is to improve how doctors monitor and treat this dangerous, fast-moving condition.
This study tests a special monitoring approach (likely using an implanted device) to help prevent serious complications after you survive cardiogenic shock in the hospital. It may help the care team detect problems earlier so treatments can start sooner.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.